Nathan's interest in the stock market arose from broader interests in theories of reification. Seeking Alpha has enabled him to challenge his own assumptions and expand his worldview.Nathan is pursuing a career path in applied sciences.Nathan was listed in "The Best Performers of Seeking Alpha: Vol 1" (2014). While other internal and external studies have compared the performance of Seeking Alpha writers, this computerized ranking was uniquely comprehensive in mining the text of articles for specific predictions, and placed Nathan within the top percentile of Seeking Alpha Contributors for his category.
Siddharth is a software engineer with a keen interest in personal finance and renewable energy. He blogs at http://www.s1dd.com at night and makes embeddable financial widgets and portals at http://www.chartiq.com/ by day.
I am a full-time college student that has always had interest in the stock market. My uncle initially got me involved several years ago and I have continued watching the stock market and a little profit here and there. I graduate in May and I hope to really get involved and become more knowledgable about the stock market. I still find it very complex, but I am willing to do my homework and become educated over time. As for me I live in Kansas and am married with no kids, and after I graduate and take boards I hope to buy a dog…or two.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.